Most of the current KRAS inhibitors did not have targeted delivery systems, which limited their efficacy in tumor targeting.[105] Engineered bacteria or microbial components can serve as effective delivery systems due to their tumor targeting property.[105, 106] Some bacteria can remove metabolic waste from tumors or provide essential nutrients for antitumor immunity. The gene discussed is KRAS; the disease is neoplasm.